RE:RE:TIGIT class of checkpoint inhibitors fails with Keytruda July 11, 2023 - Novaartis retreats from TIGIT - hands Tigit candidate back to Chinese company BiGene.
In a SEC filing today, the Chinese drugmaker said the two companies agreed yesterday to mutually terminate the option agreement for ociperlimab with immediate effect. As a result, BeiGene’s Swiss unit will regain full global rights to the drug.
The end of the agreement means the Big Pharma will no longer proceed with a phase 3 study of ociperlimab in non-small cell lung cancer (NSCLC) or its phase 2 study of the drug in triple negative breast cancer, the spokesperson added.
Once hailed as the future of immuno-oncology, the hopes for TIGITs were thrown into doubt by the high-profile phase 3 failures of Roche’s tiragolumab last year.
https://www.fiercebiotech.com/biotech/novartis-retreats-tigit-handing-300m-candidate-back-beigene